SEARCH

SEARCH BY CITATION

References

  • 1
    Steensma DP,Heptinstall KV,Johnson VM, et al. Common troublesome symptoms and their impact on health-related quality of life (QoL) in 359 patients with myelodysplastic syndromes (MDS): results of an internet-based survey. Leukemia Res. 2007; 31( suppl 1): S106. Abstract P123.
  • 2
    Moyo V,Lefebvre P,Duh MS,Yektashenas B,Mundle S. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol. 2008; 87: 527-536.
  • 3
    Mundle S. Advances in erythropoietic growth factor therapy for myelodysplastic syndromes. Exp Opin Biol Ther. 2006; 6: 1099-1104.
  • 4
    Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol. 1995; 89: 67-71.
  • 5
    Tehranchi R. Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes. Med Oncol. 2006; 23: 37-49.
  • 6
    Aloe Spiriti MA,Latagliata R,Niscola P, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol. 2005; 84: 167-176.
  • 7
    Cheson BD,Bennett JM,Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000; 96: 3671-3674.
  • 8
    Egger M,Smith GD,Altman DG. Systematic Reviews in Health Care: Meta-Analysis in Context, 2nd ed. London, United Kingdom: BMJ Publishing Group; 2001.
  • 9
    Di Raimondo F,Longo G,Cacciola EJR, et al. A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. Eur J Haematol. 1996; 56: 7-11.
  • 10
    Stasi R,Brunetti M,Bussa S, et al. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin Cancer Res. 1997; 3: 733-739.
  • 11
    Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol. 1998; 103: 1070-1074.
  • 12
    Rigolin GM,Porta MD,Bigoni R, et al. rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors response by fluorescence in situ hybridisation on May-Grunwald-Giemsa-stained bone marrow samples. Br J Haematol. 2002; 119: 652-659.
  • 13
    Terpos E,Mougiou A,Kouraklis A, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol. 2002; 118: 174-180.
  • 14
    Clavio M,Nobili F,Balleari E, et al. Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report. Eur J Haemaol. 2004; 72: 113-120.
  • 15
    Mele G,Musto C,Matera R, et al. High-dose of epoetin alfa in patients with low-risk myelodysplastic syndromes (MDS): a single institution experience [abstract]. Blood (ASH Annual Meeting Abstracts). 2004; 104. Abstract 4703.
  • 16
    Patton JF,Sullivan T,Mun Y,Reeves T,Rossi G,Wallace JF. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome. J Support Oncol. 2005; 3: 419-426.
  • 17
    Hansen PB,Johnsen HE,Hippe E, et al. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes. Am J Hematol. 1993; 44: 229-236.
  • 18
    Negrin RS,Stein R,Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 1996; 87: 4076-4081.
  • 19
    Economopoulos T,Mellou S,Papageorgiou E, et al. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin. Leukemia. 1999; 13: 1009-1012.
  • 20
    Stasi R,Pagano A,Terzoli E, et al. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. Br J Haematol. 1999; 105: 141-148.
  • 21
    Mantovani L,Lentini G,Hentschel B, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol. 2000; 109: 367-375.
  • 22
    Casadevall N,Durieux P,Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004; 104: 321-327.
  • 23
    Balleari E,Rossi E,Clavio M, et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol. 2006; 85: 174-180.
  • 24
    Park S,Grabar S,Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008; 111: 574-582.
  • 25
    Kasper C,Zahner J,Sayer HG. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. J Cancer Res Clin Oncol. 2002; 128: 497-502.
  • 26
    Hellstrom-Lindberg E,Gulbrandsen N,Lindberg G, et al. A validated decision model for treating anemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003; 120: 1037-1046.
  • 27
    Jadersten M,Montgomery SM,Dybedal I,Porwit-MacDonald A,Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood. 2005; 106: 803-811.
  • 28
    Kantarjian H,Issa JP,Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106: 1794-1803.
  • 29
    Schiller GJ,Slack J,Hainsworth JD, et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol. 2006; 24: 2456-2464.
  • 30
    Candoni A,Raza A,Silvestri F, et al. Response rates and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes. Ann Hematol. 2005; 84: 479-481.
  • 31
    Raza A,Reeves JA,Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008; 111: 86-93.
  • 32
    List A,Dewald G,Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5 q deletion. N Engl J Med. 2006; 355: 1456-1465.
  • 33
    Golshayan A-R,Jin T,Maciejewski J, et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol. 2007; 137: 125-132.
  • 34
    Mundle SD. Erythropoiesis-stimulating agents versus RBC transfusions in MDS: comparison of long-term outcomes. Future Oncol. 2007; 3: 397-403.
  • 35
    Balducci L. Transfusion independence in patients with myelodysplastic syndromes. Cancer. 2006; 106: 2087-2094.
  • 36
    Berlin J,Santanna J,Schmid CH,Szczech LA,Feldman H. Individual patient-versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med. 2002; 21: 171-187.
  • 37
    Greenberg P,Cox C,LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-2088.